From 862ae0e94751f25b3220ab1edd4090d6b09e58ad Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:16:17 +0000 Subject: [PATCH 1/2] extract: 2025-12-01-who-glp1-guidelines-behavioral-therapy-combination Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...t cost impact inflationary through 2035.md | 6 +++++ ...ients-undermining-chronic-use-economics.md | 6 +++++ ...elines-behavioral-therapy-combination.json | 26 +++++++++++++++++++ ...idelines-behavioral-therapy-combination.md | 13 +++++++++- 4 files changed, 50 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2dee6466..50f2b5d4 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -83,6 +83,12 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment. + +### Additional Evidence (challenge) +*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18* + +WHO's conditional recommendation structure and behavioral therapy requirement suggest the 'chronic use model' framing may be incomplete. The guideline establishes medication-plus-behavioral-therapy as the standard, not medication alone, which may have different economics than the pure pharmaceutical model. WHO also announced it will develop 'an evidence-based prioritization framework to identify which adults with obesity should be prioritized for GLP-1 treatment'—implying targeted use rather than universal chronic treatment. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index bb963346..1a2e85d0 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -71,6 +71,12 @@ Digital behavioral support may partially solve the persistence problem: UK study BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers. + +### Additional Evidence (extend) +*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-18* + +WHO's conditional recommendation requiring behavioral therapy combination provides international regulatory support for adherence interventions. The guideline explicitly states GLP-1s should be 'combined with intensive behavioral therapy to maximize and sustain benefits'—directly addressing the persistence problem by making behavioral support the standard of care rather than an optional add-on. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json b/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json new file mode 100644 index 00000000..cbae2c17 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json @@ -0,0 +1,26 @@ +{ + "rejected_claims": [ + { + "filename": "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 3, + "rejected": 1, + "fixes_applied": [ + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:set_created:2026-03-18", + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" + ], + "rejections": [ + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-18" +} \ No newline at end of file diff --git a/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md b/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md index 338aa443..c201755b 100644 --- a/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md +++ b/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md @@ -7,9 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: guideline -status: unprocessed +status: enrichment priority: high tags: [who, glp-1, obesity, guidelines, behavioral-therapy, global-health, equity, access, semaglutide, tirzepatide, liraglutide] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -62,3 +66,10 @@ This is worth a separate archive from the basic WHO announcement because the beh PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: WHO formal guideline establishing behavioral therapy + GLP-1 as global standard of care — this changes the economic model analysis since behavioral support is now the baseline, not an add-on EXTRACTION HINT: The conditional recommendation structure and the behavioral therapy requirement are the extractable elements. The basic fact of WHO approving GLP-1s is in the existing archive; this archive is specifically about the standard-of-care implications. + + +## Key Facts +- WHO issued conditional recommendations for liraglutide, semaglutide, and tirzepatide in obesity treatment on 2025-12-01 +- WHO guideline was published simultaneously in JAMA +- WHO will develop an evidence-based prioritization framework for GLP-1 treatment by 2026 +- Conditionality based on: limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications From 6bcf7df0b3f07e304a89f68566a1259468bdc38a Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:17:10 +0000 Subject: [PATCH 2/2] auto-fix: strip 2 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- 2 files changed, 2 insertions(+), 2 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 50f2b5d4..bf3d0570 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -79,7 +79,7 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1a2e85d0..40852332 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -67,7 +67,7 @@ Digital behavioral support may partially solve the persistence problem: UK study ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.